Evidence map›Paper›PMID 38554151›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2024

Pathogenic effects of Leu200Pro and Arg387His VRK1 protein variants on phosphorylation targets and H4K16 acetylation in distal hereditary motor neuropathy.

Aurora Campos-Díaz, Patricia Morejón-García, Eva Monte-Serrano, David Ros-Pardo, Iñigo Marcos-Alcalde, Paulino Gómez-Puertas, Pedro A Lazo

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Aurora Campos-DíazMolecular Mechanisms of Cancer Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, 37007, Salamanca, Spain.ORCID 0000-0002-6213-3410
Patricia Morejón-GarcíaMolecular Mechanisms of Cancer Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, 37007, Salamanca, Spain.ORCID 0000-0001-5691-5320
Eva Monte-SerranoMolecular Mechanisms of Cancer Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, 37007, Salamanca, Spain.ORCID 0000-0002-0865-2244
David Ros-PardoMolecular Modeling Group, Centro de Biología Molecular Severo Ochoa, CBMSO (CSIC-UAM), 28040, Madrid, Spain.
Iñigo Marcos-AlcaldeMolecular Modeling Group, Centro de Biología Molecular Severo Ochoa, CBMSO (CSIC-UAM), 28040, Madrid, Spain.ORCID 0000-0002-0674-6423
Paulino Gómez-PuertasMolecular Modeling Group, Centro de Biología Molecular Severo Ochoa, CBMSO (CSIC-UAM), 28040, Madrid, Spain.ORCID 0000-0003-3131-729X
Pedro A LazoMolecular Mechanisms of Cancer Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, 37007, Salamanca, Spain. pedro.lazo@csic.es.ORCID 0000-0001-8997-3025
Centro de Biología Molecular Severo Ochoa · ESConsejo Superior de Investigaciones Científicas · ESInstituto de Investigación Biomédica de Salamanca · ES

Funding

Agencia Estatal de Investigación PID2019-105610RB-I00Agencia Estatal de Investigación PID2022-139598OB-I00Agencia Estatal de Investigación RED2018-102801-TAgencia Estatal de Investigación RTC-2017-6494-1Agencia Estatal de Investigación RTI2018-094434-B-I00Consejería de Educación, Junta de Castilla y León CLC-2017-01Consejería de Educación, Junta de Castilla y León CSI004-18Consejería de Educación, Junta de Castilla y León CSI264P20Ministerio de Universidades FPU16/01883Ministerio de Universidades FPU20/02978
6 · The paper itself

Abstract

Rare recessive variants in the human VRK1 gene are associated with several motor neuron diseases (MND), such as amyotrophic lateral sclerosis, spinal muscular atrophy, or distal hereditary motor neuropathies (dHMN). A case with dHMN carrying two novel VRK1 gene variants, expressing Leu200Pro (L200P) and Arg387His (R387H) variant proteins, identified that these protein variants are functionally different. The Leu200Pro variant shares with several variants in the catalytic domain the loss of the kinase activity on different substrates, such as histones, p53, or coilin. However, the distal Arg387His variant and the distal Trp375* (W375X) chinese variant, both located at the end of the low complexity C-terminal region and proximal to the termination codon, retain their catalytic activity on some substrates, and mechanistically their functional impairment is different. The L200P variant, as well as most VRK1 pathogenic variants, impairs the phosphorylation of BAF and histone H4K16 acetylation, which are required for DNA attachment to the nuclear envelope and chromatin accessibility to DNA repair mechanisms, respectively. The R387H variant impairs phosphorylation of H2AX, an early step in different types of DNA damage responses. The functional variability of VRK1 protein variants and their different combinations are a likely contributor to the clinical phenotypic heterogeneity of motor neuron and neurological diseases associated with rare VRK1 pathogenic variants. KEY MESSAGES: VRK1 variants implicated in motor neuron diseases are functionally different. The L200P variant is kinase inactive, and the R387H variant is partially active. VRK1 variants alter H4K16 acetylation and loss of coilin and BAF phosphorylation. VRK1 variants alter Cajal bodies and DNA damage responses. VRK1 variant combination determines the neurological phenotype heterogeneity.

Indexed as

HistonesIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesAcetylationDNA-Binding ProteinsFemaleHumansMaleMiddle AgedMotor Neuron DiseaseNuclear ProteinsPhosphorylationBANF1 protein, humanDNA-Binding ProteinsHistonesIntracellular Signaling Peptides and ProteinsNuclear ProteinsProtein Serine-Threonine KinasesVRK1 protein, humanChromatinDNA damageEpigeneticsHistone acetylationMotor neuron diseasesVRK1

Identifiers

PMID38554151
PMCPMC11106162
OpenAlexW4393342322

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.